vs

Side-by-side financial comparison of PERDOCEO EDUCATION Corp (PRDO) and GeneDx Holdings Corp. (WGS). Click either name above to swap in a different company.

PERDOCEO EDUCATION Corp is the larger business by last-quarter revenue ($211.6M vs $121.0M, roughly 1.7× GeneDx Holdings Corp.). On growth, GeneDx Holdings Corp. posted the faster year-over-year revenue change (26.5% vs 20.0%). PERDOCEO EDUCATION Corp produced more free cash flow last quarter ($37.9M vs $-7.4M). Over the past eight quarters, GeneDx Holdings Corp.'s revenue compounded faster (39.2% CAGR vs 12.2%).

Perdoceo Education Corporation (PRDO) is a public company that owns five for-profit universities in the United States: American Intercontinental University, Colorado Technical University, California Southern University, Trident University International, and University of St. Augustine for Health Sciences. The company was previously known as Career Education Corporation.

GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...

PRDO vs WGS — Head-to-Head

Bigger by revenue
PRDO
PRDO
1.7× larger
PRDO
$211.6M
$121.0M
WGS
Growing faster (revenue YoY)
WGS
WGS
+6.5% gap
WGS
26.5%
20.0%
PRDO
More free cash flow
PRDO
PRDO
$45.3M more FCF
PRDO
$37.9M
$-7.4M
WGS
Faster 2-yr revenue CAGR
WGS
WGS
Annualised
WGS
39.2%
12.2%
PRDO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PRDO
PRDO
WGS
WGS
Revenue
$211.6M
$121.0M
Net Profit
$-17.7M
Gross Margin
69.6%
Operating Margin
19.8%
-11.8%
Net Margin
-14.6%
Revenue YoY
20.0%
26.5%
Net Profit YoY
-424.9%
EPS (diluted)
$0.55
$-0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRDO
PRDO
WGS
WGS
Q4 25
$211.6M
$121.0M
Q3 25
$211.9M
$116.7M
Q2 25
$209.6M
$102.7M
Q1 25
$213.0M
$87.1M
Q4 24
$176.4M
$95.6M
Q3 24
$169.8M
$76.9M
Q2 24
$166.7M
$70.5M
Q1 24
$168.3M
$62.4M
Net Profit
PRDO
PRDO
WGS
WGS
Q4 25
$-17.7M
Q3 25
$39.9M
$-7.6M
Q2 25
$41.0M
$10.8M
Q1 25
$43.7M
$-6.5M
Q4 24
$5.4M
Q3 24
$38.3M
$-8.3M
Q2 24
$38.4M
$-29.2M
Q1 24
$39.4M
$-20.2M
Gross Margin
PRDO
PRDO
WGS
WGS
Q4 25
69.6%
Q3 25
72.4%
Q2 25
69.0%
Q1 25
67.1%
Q4 24
69.2%
Q3 24
62.2%
Q2 24
60.9%
Q1 24
59.9%
Operating Margin
PRDO
PRDO
WGS
WGS
Q4 25
19.8%
-11.8%
Q3 25
24.1%
-2.8%
Q2 25
24.5%
8.7%
Q1 25
24.3%
-5.2%
Q4 24
21.1%
9.2%
Q3 24
26.4%
-10.1%
Q2 24
27.6%
-15.0%
Q1 24
27.5%
-21.9%
Net Margin
PRDO
PRDO
WGS
WGS
Q4 25
-14.6%
Q3 25
18.8%
-6.5%
Q2 25
19.6%
10.5%
Q1 25
20.5%
-7.5%
Q4 24
5.7%
Q3 24
22.5%
-10.8%
Q2 24
23.0%
-41.4%
Q1 24
23.4%
-32.4%
EPS (diluted)
PRDO
PRDO
WGS
WGS
Q4 25
$0.55
$-0.59
Q3 25
$0.60
$-0.27
Q2 25
$0.62
$0.36
Q1 25
$0.65
$-0.23
Q4 24
$0.46
$0.25
Q3 24
$0.57
$-0.31
Q2 24
$0.57
$-1.10
Q1 24
$0.59
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRDO
PRDO
WGS
WGS
Cash + ST InvestmentsLiquidity on hand
$111.0M
$171.3M
Total DebtLower is stronger
$54.5M
Stockholders' EquityBook value
$972.4M
$308.2M
Total Assets
$1.2B
$523.7M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRDO
PRDO
WGS
WGS
Q4 25
$111.0M
$171.3M
Q3 25
$159.5M
$155.1M
Q2 25
$172.1M
$134.6M
Q1 25
$132.1M
$159.2M
Q4 24
$109.1M
$141.2M
Q3 24
$238.0M
$116.5M
Q2 24
$127.9M
$106.9M
Q1 24
$125.8M
$112.9M
Total Debt
PRDO
PRDO
WGS
WGS
Q4 25
$54.5M
Q3 25
$54.8M
Q2 25
$55.1M
Q1 25
$55.5M
Q4 24
$55.8M
Q3 24
$56.1M
Q2 24
$56.3M
Q1 24
$56.3M
Stockholders' Equity
PRDO
PRDO
WGS
WGS
Q4 25
$972.4M
$308.2M
Q3 25
$997.9M
$292.3M
Q2 25
$984.6M
$277.1M
Q1 25
$970.3M
$257.4M
Q4 24
$959.5M
$245.2M
Q3 24
$935.4M
$204.5M
Q2 24
$899.5M
$194.0M
Q1 24
$866.1M
$207.2M
Total Assets
PRDO
PRDO
WGS
WGS
Q4 25
$1.2B
$523.7M
Q3 25
$1.3B
$493.9M
Q2 25
$1.3B
$463.9M
Q1 25
$1.3B
$446.4M
Q4 24
$1.2B
$419.4M
Q3 24
$1.1B
$408.8M
Q2 24
$1.1B
$389.1M
Q1 24
$1.1B
$394.5M
Debt / Equity
PRDO
PRDO
WGS
WGS
Q4 25
0.18×
Q3 25
0.19×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.23×
Q3 24
0.27×
Q2 24
0.29×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRDO
PRDO
WGS
WGS
Operating Cash FlowLast quarter
$40.1M
$-3.1M
Free Cash FlowOCF − Capex
$37.9M
$-7.4M
FCF MarginFCF / Revenue
17.9%
-6.1%
Capex IntensityCapex / Revenue
1.1%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$216.7M
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRDO
PRDO
WGS
WGS
Q4 25
$40.1M
$-3.1M
Q3 25
$41.2M
$15.8M
Q2 25
$78.8M
$10.4M
Q1 25
$65.1M
$10.2M
Q4 24
$17.6M
$-3.2M
Q3 24
$51.0M
$-4.4M
Q2 24
$38.5M
$-4.5M
Q1 24
$54.5M
$-16.4M
Free Cash Flow
PRDO
PRDO
WGS
WGS
Q4 25
$37.9M
$-7.4M
Q3 25
$39.4M
$9.6M
Q2 25
$76.0M
$8.1M
Q1 25
$63.4M
$4.1M
Q4 24
$16.0M
$-6.2M
Q3 24
$50.0M
$-5.0M
Q2 24
$37.7M
$-5.9M
Q1 24
$53.3M
$-16.9M
FCF Margin
PRDO
PRDO
WGS
WGS
Q4 25
17.9%
-6.1%
Q3 25
18.6%
8.2%
Q2 25
36.3%
7.8%
Q1 25
29.8%
4.7%
Q4 24
9.1%
-6.5%
Q3 24
29.4%
-6.6%
Q2 24
22.6%
-8.3%
Q1 24
31.7%
-27.0%
Capex Intensity
PRDO
PRDO
WGS
WGS
Q4 25
1.1%
3.6%
Q3 25
0.9%
5.3%
Q2 25
1.3%
2.3%
Q1 25
0.8%
7.0%
Q4 24
0.9%
3.2%
Q3 24
0.6%
0.8%
Q2 24
0.5%
1.9%
Q1 24
0.7%
0.7%
Cash Conversion
PRDO
PRDO
WGS
WGS
Q4 25
Q3 25
1.03×
Q2 25
1.92×
0.96×
Q1 25
1.49×
Q4 24
-0.59×
Q3 24
1.33×
Q2 24
1.00×
Q1 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRDO
PRDO

CTU$107.0M51%
AIUS$60.8M29%
University Of St Augustine For Health Sciences Llc$43.7M21%
Other$1.1M1%

WGS
WGS

Diagnostic Test Third Party Insurance$101.1M84%
Diagnostic Test Institutional Customers$15.5M13%
Other$3.4M3%

Related Comparisons